A systematic review and meta-analysis on the efficacy and safety of traditional Chinese patent medicine Jinqi Jiangtang Tablet in the treatment of type 2 diabetes. (December 2019)

• Record Type: Journal Article
• Authors: Gao, Huijuan; Yang, Yingxi; Deng, Jianqing; Liang, Jiaqi; Zhang, Weihua; Feng, Xingzhong
• Is Part Of: Complementary therapies in medicine. Volume 47(2019)
• Publication Date: 2019-12
• Subjects: Systematic review -- Meta-analysis -- Type 2 diabetes -- Jinqi Jiangtang tablet -- Randomized controlled trials; Alternative medicine -- Periodicals; Complementary Therapies -- Periodicals; Médecines parallèles -- Périodiques; Thérapeutique -- Périodiques; Alternative medicine; Electronic journals; Periodicals; 615.5
• DOI: 10.1016/j.ctim.2019.01.016
• Languages: English
• ISSNs: 0965-2299

Abstract

Highlights: Jinqi Jiangtang tablet (JQJTT) combined with conventional therapy performed good in terms of effective rate. There was more significant reduction associated with FBG, 2h PBG and HbA1c in JQJTT plus conventional therapy group. In terms of FINS, PINS and HOMA-IR, there was a better performance in JQJTT plus conventional therapy group. There was a more significant improvement associated with LDL-C, TC, TG in JQJTT plus conventional therapy group. Abstract: Introduction: At present, a large number of people in the world are suffering from type 2 diabetes (T2DM), so it is urgent to develop effective treatment measures of T2DM. In China, many clinical studies have shown that Jinqi Jiangtang Tablet (JQJTT), a traditional Chinese patent medicine (TCPM), has a good effect in the treatment of T2DM. This systematic review and meta-analysis is intended to assess the efficacy and safety of JQJTT plus conventional therapy in the treatment of T2DM. Methods: Seven electronic databases were searched to include in eligible studies published from inception to May 24, 2018. Randomized controlled trials (RCTs) of JQJTT in combination with the conventional therapy versus conventional therapy alone or combined with placebo were included. The two reviewers independently conducted data extraction and quality assessment. For different variable types, the outcome measures were expressed as risk ratios (RRs) or mean differences (MDs). According to the value of I 2, a fixed or random effect model was used for statistical analysis. Results: Seventeen studies conducted in China were identified in this systematic review, which included 1, 425 participants. The meta-analysis on the effective rate of the comparison groups showed a significant difference in favor of the JQJTT group (RR 1.34; 95%CI [1.02, 1.75]; p = 0.04). In addition, the results showed a statistically significant reduction in FBG (MD −0.85; 95%CI [−1.03, −0.68]; p < 0.00001), 2hPG (MD −1.95; 95%CI [−2.33, −1.56]; p < 0.00001), HbA1c (MD −0.76; 95%CI [−1.03, −0.49]; p < 0.00001), FINS (MD −3.05; 95%CI [−3.69, −2.42]; p < 0.00001), PINS (MD −10.22; 95%CI [−13.93, −6.50]; p < 0.00001), HOMA-IR (MD −1.11; 95%CI [−1.55, −0.68]; p < 0.00001), LDL-C (MD −0.37; 95%CI [−0.63, −0.11]; p = 0.006), TC (MD −0.46; 95%CI [−0.85, −0.08]; p = 0.02), TG (MD −0.34; 95%CI [−0.47, −0.20]; p < 0.00001) with JQJTT plus conventional therapy versus conventional therapy alone. There was no statistical difference between the two comparison groups in HDL-C, total incidence of adverse events and incidence of hypoglycemia. Conclusion: The available evidence indicates that JQJTT combined with conventional therapy for treating T2DM has a good performance in regulating glycolipid metabolism and improving insulin resistance. However, due to the limitations of this systematic review, the results should be interpreted with caution.